| Name | Title | Contact Details |
|---|
AmeriChoice of New York is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Robin Healthcare is an innovative healthcare partner that combines the power of artificial intelligence (AI), voice recognition, and domestic virtual medical scribes and care coordinators to solve healthcare biggest challenges and inefficiencies.
Care n' Care Health Plan is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Solera is changing lives by guiding people to better health solutions that work. Solera`s value-based technology platform enables successful interventions that address the most prevalent and costly chronic conditions. Solera matches consumers to their best-fit solution within carefully curated networks of digital and community-based point solutions and drives superior engagement and outcomes by managing performance. Solera`s technology platform serves payers and employers by streamlining, integrating, and creating accountability in the point solution ecosystem.
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.